Skip to main content
Clinical Trials/CTRI/2023/09/057492
CTRI/2023/09/057492
Not Yet Recruiting
Phase 2

A pilot clinical trial to evaluate the effectiveness of Linga chendooram in the management of Uthiravatha suronitham (Rheumatoid arthritis) - Nil

I0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Sponsor
I
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
I

Eligibility Criteria

Inclusion Criteria

  • Onset of arthritis after the age of 16 years
  • Positive for rheumatoid factor (RF)
  • Anti \- CCP
  • Either an erythrocyte sedimentation rate (ESR) of greater than 30 mm/hr OR
  • C\-reactive protein level greater than 1\.0 mg/dl (normal less than 0\.4\)
  • Diagnosis of Uthira Vatha Suronitham, as defined by fulfilling at least more than two articular involvements
  • Morning stiffness
  • Willing to take study medication
  • Willing to follow diet restriction
  • Patients giving informed consent (Signed or oral witnessed, according to local regulations) before any Protocol specific

Exclusion Criteria

  • Uncontrolled Diabetes Mellitus
  • Uncontrolled Hypertension
  • Cardiac disease
  • Renal disease
  • Neurological disorders
  • Pregnancy and lactation
  • History of alcohol or substance abuse
  • Active infection, or chronic or persistent infection that might
  • worsen with immunosuppressive treatment
  • Patients who have already participated in a new drug study in

Outcomes

Primary Outcomes

Not specified

Similar Trials